---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-001871"
form_type: "8-K"
ticker: "WINT"
cik: "0000946486"
company_name: "WINDTREE THERAPEUTICS INC /DE/"
filed_at: "2024-01-22T23:59:59+00:00"
generated_at: "2026-06-06T20:57:20.528401+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Windtree receives Nasdaq deficiency notice for bid price below $1.00

## Summary
- Deficiency letter received January 22, 2024; common stock (WINT) remains listed on Nasdaq Capital Market.
- Company has until July 22, 2024 to regain compliance by closing at $1.00+ for 10 consecutive business days.
- If not compliant by July 22, a second 180-day period may be available if other listing standards are met.
- Company intends to monitor bid price and consider all options, including a reverse stock split.
- No assurance that compliance will be achieved or that delisting will be avoided.

## SEC filing metadata
- accession: 0001437749-24-001871
- form_type: 8-K
- ticker: WINT
- cik: 0000946486
- company_name: WINDTREE THERAPEUTICS INC /DE/
- filed_at: 2024-01-22T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/946486/000143774924001871/0001437749-24-001871-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/946486/000143774924001871/wint20240122_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-001871
- JSON: https://secwatch.observer/filing/0001437749-24-001871.json
- Plain text: https://secwatch.observer/filing/0001437749-24-001871.txt

## Key facts
- Listing & Compliance Notices
  WINDTREE THERAPEUTICS INC /DE/ received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: January 22, 2024, Windtree Therapeutics, Inc. (the “Company”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 31 consecutive business days, the closing bid price for the Company’s common stock, par value $0.001 per share (the “Common Stock”) has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (“Rule 5550(a)(2)”). The Nasdaq deficiency letter has no immediate effect on the lis
  evidence_url: https://www.sec.gov/Archives/edgar/data/946486/000143774924001871/0001437749-24-001871-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.